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Abstract
Hepatitis C virus (HCV) genotype (GT) 3 is the second most prevalent of the seven HCV genotypes and exhibits the greatest
resistance to the highly potent, direct-acting antivirals (DAAs) that are currently in use. Previously a stable cell line
harbouring the S52 GT3 sub-genomic replicon (SGR) was established, but this SGR was unable to robustly replicate
transiently. As transient SGRs are a critical tool in the development of DAAs, and in the study of viral resistance, we sought
to establish a transient SGR system based on S52. Next-generation sequencing was used to identify putative culture-
adaptive substitutions that had arisen during long-term selection of the S52 SGR. A subset of these substitutions was built
back into the S52 SGR in the context of a CpG/UpA-low luciferase reporter, with a single point mutation in NS4A conferring
the greatest replication capability upon S52. Modification of the innate immune-sensing pathways of Huh7.5 hepatoma cells
by expression of the parainfluenza virus type 5 V protein and SEC14L2 resulted in a further enhancement of S52 replication.
Furthermore, this transiently replicating SGR showed genotype-specific differences in sensitivity to two clinically relevant
NS5A DAAs. In conclusion, we report that a single substitution in NS4A, coupled with host cell modifications, enabled robust
levels of transient replication by the GT3 S52 SGR. This system will have beneficial uses in both basic research into the
unique aspects of GT3 biology and drug discovery.
INTRODUCTION
Approximately 170million people worldwide are estimated
to be chronically infected with hepatitis C virus (HCV) [1],
leading to fibrosis, cirrhosis, liver failure and hepatocellular
carcinoma (HCC) [2]. To date seven genotypes have been
identified [3], within which a number of subtypes show dif-
ferent global distribution patterns. Genotype (GT) 1 is most
prevalent worldwide, with GT1b being the most common
genotype in northern Europe. GT3 is the most common GT
in low- to middle-income countries (LMIC), accounting for
44% of cases. In particular, 70% of HCV infections in South
Asia (Pakistan, India and Thailand) are GT3, and it is
thought that the global dissemination of GT3 is partially
due to population migration from this area of the world.
Consistent with this, GT3 is prevalent in parts of Western
Europe, especially the UK where it accounts for 44% of
HCV cases. Overall, it has been estimated that over 50mil-
lion people are infected with HCV GT3 [1].
Recent years have seen the development of potent, direct-act-
ing antivirals (DAAs) to treat HCV. These compounds target
the virus NS3 protease (e.g. simeprevir), NS5B RNA polymer-
ase [e.g. the nucleoside analogue sofosbuvir (SOF)] and NS5A
[e.g. daclatasvir (DCV) or ledipasvir (LDV)]. DAAs are better
tolerated than the previous interferon-a (IFNa)-based regi-
mens, with sustained virological response (SVR) rates of close
to 100% for GT1 patients without cirrhosis routinely reported
[4]. However, IFNa-free therapies are less effective against
GT3. GT3 patients who are non-cirrhotic and treatment-
naive exhibit SVR of 67–96% following a 12–16-week SOF/
ribavirin regimen, with added benefits of 24weeks of treat-
ment (86–91%) and inclusion of DCV (96%). Patients with
compensated cirrhosis who are treatment experienced typi-
cally show SVR rates of 21–62% even in trials including com-
bination therapy of DCV and SOF [5–11].
GT3 infection is associated with a more rapid progression
of liver disease and a direct correlation with metabolic
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syndrome. This leads to a higher incidence of insulin resis-
tance, steatosis (fatty liver) and hepatocellular carcinoma
compared to other GTs [12]. This is of increasing concern
given the results of clinical trials showing that HCV patients
with compensated cirrhosis respond less well to all-oral
DAA regimens and that GT3 patients with cirrhosis
respond minimally to treatment [13].
Development of new therapies has relied upon the sub-
genomic replicon (SGR) system, which was first reported
for GT1b [14]. Subsequently the efficiently replicating GT2a
isolate JFH-1 [15] has become widely used throughout the
field of HCV research. Initially the SGR constructs con-
tained a neomycin phosphotransferase selectable marker
allowing the establishment of stable cell lines harbouring
the SGR. Critical for the development of DAAs was the
availability of a transient, luciferase-based, SGR, but such a
system does not yet exist for GT3. Three separate GT3
SGRs derived from two different patient isolates have been
reported, but neither of these shows robust levels of replica-
tion in short-duration, transient experiments. The S52 SGR
replicates to high levels during selection and generates levels
of HCV RNA comparable to JFH-1, but has not been dem-
onstrated to replicate transiently using a luciferase reporter
[16]. The S310/A SGR has been shown to replicate tran-
siently but luciferase levels were several orders of magnitude
lower than the input translation [17], and another S52-
based SGR which was culture-adapted in Huh7-Lunet cells
showed detectable levels of replication at 7 days post-trans-
fection [18].
The majority of studies with GT3 have thus far used chime-
ric SGRs, in which fragments of GT3 isolates, or consensus
sequences, were used to replace the corresponding coding
regions in efficiently replicating GT1 or GT2 backbones.
These have been used to show differential sensitivity to
NS5A and NS5B inhibitors in vitro of GT3 sequences com-
pared to wild-type controls [19–21]. Recombinant SGRs are
limited in that they do not allow study of the cognate inter-
actions between viral proteins in the replication complex,
and this may provide a hindrance to development of combi-
nation therapies. An intact (non-chimeric) GT3 SGR that
replicates transiently would be of benefit to understanding
the baseline resistance of GT3 to the DAAs, and for devel-
opment of new DAAs with efficacy against GT3.
To this end we report here the establishment of a robustly
replicating transient GT3 SGR. This required both SGR
modifications, including additional culture-adaptive muta-
tions, and host cell alterations such as expression of inhibi-
tors of the innate antiviral response.
RESULTS
The S52 SGR does not replicate transiently but can
establish stable SGR-harbouring cells following
selection
The S52 GT3a SGR [16] was assembled from a consensus
full-length DNA clone of the S52 clinical isolate [22], and
consists of a bicistronic construct containing a neomycin
phosphotransferase/firefly luciferase (Feo) reporter under
the translational control of the HCV internal ribosome
entry site (IRES), together with the NS3-5B coding region
under the control of an EMCV IRES. Importantly it was
engineered to contain three culture adaptive substitutions
(T1056A, T1429I and S2204I by H77 numbering) and was
thus called S52(AII) [16]. For clarity it will be named S52
hereafter. To test for transient replication of the S52 SGR, in
vitro transcribed RNA was transfected into Huh7.5 cells by
electroporation and compared with the GT2a JFH-1 SGR.
As shown in Fig. 1, the S52 SGR was indistinguishable from
the GND (polymerase-inactive) mutant of JFH-1 and did
not replicate to detectable levels in Huh7.5 cells.
As the S52 SGR has been reported to establish stable repli-
con-harbouring cells [16], we sought to reproduce this
observation. In vitro transcribed S52 SGR RNA was electro-
porated into Huh7.5 cells and selected with G418 for three
weeks, after which time a small number of colonies of stable
SGR-harbouring cells were obtained. These cells were
pooled into a polyclonal population and maintained under
G418 selection. As can be seen in Fig. 1(b), these cells exhib-
ited steady-state levels of firefly luciferase activity that were
comparable to that in cells stably harbouring the corre-
sponding JFH-1 SGR and considerably higher that the Con1
(GT1b) SGR. NS5A expression was analysed by WB,
with only a single species of NS5A being observed in the
S52 SGR cells consistent with the presence of the S2204I
substitution that abrogates hyperphosphorylation (Fig. 1c).
Lastly the S52 SGR-harbouring cells exhibited a similar dis-
tribution of NS5A to JFH-1 SGR-harbouring cells, with the
protein being found in punctate structures located through-
out the cytoplasm (Fig. 1d).
Additional putative culture adaptive substitutions
are acquired during selection of stable S52 SGR-
harbouring cells
The observation that the S52 SGR did not exhibit detectable
transient replication, yet was able to establish stable G418-
resistant cells, suggested that it might have acquired addi-
tional substitutions that supported higher-level replication.
To test this hypothesis, SGR RNA in these cells was ampli-
fied by RT-PCR and subjected to next-generation sequenc-
ing (NGS). Analysis of the data revealed the presence of
nine single nucleotide substitutions at greater than 20% var-
iant frequency. Seven of these were non-synonymous and
are detailed in Table 1. The three culture-adaptive substitu-
tions present in the input S52 SGR sequence (AII) at the
time of electroporation were maintained following selection,
with a frequency of 100% for all three (data not shown).
Due to the lack of linkage of the short reads obtained by
NGS, and the fact that the substitutions observed were not
present in all reads, it was not possible to determine which
combination(s) of substitutions might result in enhanced
replication. To test this we performed an additional round
of G418 selection in which we extracted total RNA from
S52 SGR-harbouring cells and re-electroporated into naïve
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Huh7.5 cells. Despite detectable luciferase in these cells elec-
troporated at 96 h post-electroporation (hpe) (data not
shown), there was not sufficient material to amplify for fur-
ther NGS. Therefore we subjected these cells to further
selection with G418 as described previously. A large number
of colonies were visible on these plates, which were pooled
to give a polyclonal population. SGR RNA in these cells was
again amplified by RT-PCR and subjected to NGS, and the
only substitutions which were detected in this second round
of sequencing were K1406N in NS3 and A1672V in NS4A
(H77 numbering). Note that these substitutions are num-
bered K1412N and A1678V in S52 but will be referred to by
H77 numbering henceforth, to comply with the accepted
convention in the HCV field. We considered that these cul-
ture-adaptive substitutions might enable higher levels of
transient replication of the S52 SGR and set out to test this
hypothesis. We therefore introduced these substitutions
back into the S52 SGR (AII) either singly or in combination.
As H1685Y (H1691Y in S52) was the most prevalent substi-
tution observed after the first round of selection (Table 1),
we also included this substitution in our analysis. Fig. 2
shows the location of these putative culture-adaptive substi-
tutions in the three-dimensional structures of the NS3 heli-
case and NS4A co-factor peptide bound to the active site of
NS3 protease. The location of K1406N within the NS3 heli-
case domain and H1685Y within the NS4A co-factor pep-
tide are highlighted in green; it was not possible to model
A1672V as it is within the hydrophobic N-terminal domain.
To act as a negative control we also generated a mutation in
the active site of the NS5B RNA-dependent RNA
0
Fig. 1. Assay for replication of S52 SGR. (a) Transient replication of the S52 SGR (AII culture adapted variant) [16] compared to either
wild-type or GND mutant JFH-1 (GT2a). Two micrograms of the indicated RNA transcripts were electroporated into Huh7.5 cells and
harvested for luciferase assay at the indicated time points. Relative luciferase units are expressed as the ratio to 4 hpe. Error bars
show standard error of the mean of three experimental repeats. (b) S52 SGR RNA was electroporated into Huh7.5 cells and selected
with 0.5mg ml 1 G418 from 48 hpe. Surviving colonies were pooled into a polyclonal population of SGR-harbouring cells. Luciferase
activity was measured in 8103 cells and presented as absolute values compared to Con1- and JFH-1 SGR-harbouring cell lines. (c)
Western blot analysis of NS5A expression in JFH-1- or S52 SGR-harbouring cells. (d) S52- and JFH-1 SGR-harbouring cells were
immunostained for NS5A (green) using a sheep polyclonal anti-NS5A serum and nuclei using DAPI. **P0.01, ****P0.0001.
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polymerase (GNN) – this mutant has been shown in many
SGRs to be replication inactive. As the transient replication
of S52 SGR has been reported to be enhanced by the modifi-
cation of the construct to include a firefly luciferase gene
with reduced CpG and UpA dinucleotide frequencies [23],
we also replaced the Feo reporter with a CpG/UpA-low fire-
fly luciferase. All of these substitutions were compared to
the parental S52 SGR and the GNN mutant. However, as
shown in Fig. 2(c), none of these substitutions enabled the
transient replication of the S52 SGR, although the single
A1672V substitution in NS4A gave higher luciferase values
than all the others.
Robust transient replication of the S52 SGR also
required modulation of the host cell environment
We considered that in addition to modifying the S52 SGR it
might be possible to enhance transient replication by
increasing the permissivity of the host cell for viral genome
replication. To achieve this we evaluated two approaches:
first, expression of the V protein from parainfluenza virus
type 5 (PIV5) – a well-characterized interferon antagonist
[24, 25]; and second, expression of the host cell protein
SEC14L2 (also known as Tocopherol-associated protein,
TAP1) [26]. SEC14L2 has been reported to enable replica-
tion of non-culture-adapted SGRs [26].
We therefore established stable Huh7.5 cell lines expressing
either the PIV5 V protein, SEC14L2 or both (the latter are
termed VSEC cells hereafter). To verify the integrity of the
cell lines, these were analysed by WB for PIV5 V protein
expression and RT-PCR for SEC14L2 RNA (Fig. 3a). To
confirm the expected activity of the PIV5 V protein, Huh7.5
and Huh7.5 V cells were transfected with an ISRE-luciferase
construct and treated with IFN-a for 6 or 12 h. As expected
there was an increase in luciferase in Huh7.5 cells treated
with IFN-a, but this was not observed in Huh7.5 V cells
(Fig. 3b), confirming that the PIV5 V protein abrogated
IFN signalling.
We then confirmed that these two proteins were able to
enhance the transient replication of a GT1b (Con1) SGR. As
expected [23], the CpG/UpA-low luciferase derivative of the
Con1 SGR replicated better than a wild-type luciferase ver-
sion in Huh7.5 cells (Fig. 3c). In addition, the presence of
either PIV5 V or SEC14L2 enhanced replication of both the
wild-type and CpG/UpA-low luciferase Con1 SGR (Fig. 3d,
e), and the presence of both proteins had an additive effect
(Fig. 3f). However, the presence of PIV5 V, SEC14L2 or
both was not sufficient to support replication of the S52
SGR with CpG/UpA-low luciferase. We then tested whether
any combination of the three culture-adaptive substitutions
(K1406N, A1672V and H1685Y) were able to exhibit detect-
able transient replication of the S52 SGR in VSEC cells. As
Table 1. Nucleotide substitutions identified during selection of the S52 SGR
Nucleotide
substitution
Amino acid substitution (S52
individual protein numbering)
Amino acid substitution (S52 polyprotein
numbering) (H77 polyprotein numbering)
% variant
frequency
Location Residue
in JFH-1
Residue
in Con1
G340C VII3L V1145L (1139) 24 NS3 V V
A1143C K380N K1412N (1406) 25 NS3 A K
C1940T A15V A1678V (1672) 33 NS4A A A
C1978T H28Y H1691Y (1685) 70 NS4A R R
A2114G E19G E1736G (1730) 34 NS4B S Q
T3048A N69K N2047K (2041) 41 NS5A L N
A3998G Q386R Q2364R (2350a) 24 NS5A S absent
Fig. 2. Culture-adaptive substitutions identified following selection of
S52 SGR-harbouring cells. Location of putative culture-adaptive sub-
stitutions on three-dimensional structures of NS3 or NS4A. In (a)
K1406 is shown in green within NS3 helicase. Proposed spring helix
shown in yellow, nucleic acid binding cleft in blue and ATP-binding
cleft shown in red. In (b) H1685 is shown in green within the NS3-
binding region of the NS4A peptide (red), and the NS3 protease-active
site shown in blue. A1672 is within the hydrophobic N terminus (not
shown on crystal structure). (c) Transient replication of the S52 SGR
culture-adaptive substitutions. The indicated substitutions were cloned
back into S52 SGR, and 2 µg RNA transcripts were electroporated into
Huh7.5 cells and harvested for luciferase assay. Luciferase activity is
presented as absolute values. Error bars show the standard error of
the mean of three experimental repeats.
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Fig. 3. Enhancement of SGR replication using low-CpG luciferase, PIV-5 V protein and SEC14L2. (a) Confirmation of PIV-5 V or
SEC14L2 expression by western blot or RT-PCR, respectively. (b) Huh7.5 or Huh7.5 V cells were transfected with an ISRE-luc plasmid
and treated with IFN-a for 6 or 12 h prior to harvest for luciferase assay. Two micrograms of the indicated SGR RNA transcripts were
electroporated into Huh7.5 (c), Huh7.5 V (d), Huh7.5 SEC14L2 (e) and Huh7.5 V+SEC14L2 (termed VSEC cells) (f). (g) For comparative
Kelly et al., Journal of General Virology 2017;98:2495–2506
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shown in Fig. 4, this was indeed the case. Compared to the
observations in Huh7.5 cells (Fig. 2a) the NS4A substitution
A1672V, either alone or in combination with the other
NS4A substitution H1685Y, enhanced replication at 96 hpe
by between 100–1000-fold. H1685Y alone, or the NS3 sub-
stitution K1406N alone, gave a 10-fold enhancement of rep-
lication. However, all other combinations did not replicate,
exhibiting similar profiles to either the parental S52 SGR or
the GNN NS5B mutant, suggesting that although these
three substitutions were able to enhance replication there
was some degree of incompatibility between them.
Validation of the transient S52 SGR for DAA
screening
The development of a transient S52 SGR opened up the pos-
sibility that this system could be used to screen for DAAs
and/or investigate resistance. As proof of principle we there-
fore focused our attention on the most active of the three
culture adaptive substitutions – A1672V. For clarity this
SGR (which also contained the CpG/UpA-low luciferase)
will be referred to as S52(A1672V). We also generated a fur-
ther derivative of S52(A1672V) containing a Y93H
(Y2065H by H77 polyprotein numbering) substitution
within domain I of NS5A – this has previously been
reported to result in DCV resistance in multiple GTs. S52
(A1672V) and the Y93H derivative were electroporated into
VSEC cells and then treated from 4 to 48 hpe with a range
of concentrations of DCV, LDV, SOF or ribavirin (Fig. 5).
As controls, VSEC cells were electroporated with either a
CpG/UpA-low Con1 (GT1b) SGR [23] or SGR-Feo-JFH-1.
From the graphs, 50% effective concentrations (EC50) were
calculated using Graphpad Prism software and are pre-
sented in Table 2. As expected, S52(A1672V) was less sensi-
tive to DCV or LDV, compared to both Con1 and JFH-1. In
addition, the Y93H substitution resulted in an extraordinary
70 000-fold decrease in sensitivity to DCV; this difference
was less pronounced for LDV as the wild-type S52
(A1672V) SGR was already highly resistant to LDV. There
was a modest difference in sensitivity of the SGR tested to
SOF and ribavirin.
Use of the transient system also revealed an additional
aspect of DAA resistance: when the stable S52 SGR-har-
bouring cells were treated with DCV at a concentration
equating to 100EC50, this resulted in the acquisition of a
Y93H resistance-associated substitution (RAS) (as assessed
by RT-PCR and Sanger sequencing – data not shown). The
resulting DCV-resistant SGR replicated at a similar level to
the wild-type SGR (Fig. 6a) and thus did not exhibit a fit-
ness cost in acquiring DCV resistance. A similar observation
was made when enumerating colony formation following
electroporation of either SGR-Feo-S52 wild-type or Y93H
(Fig. 6b). However, in the transient assay Y93H exhibited a
significant fitness cost, replicating over 96 hpe at less than
50% of wild type (Fig. 6c).
DISCUSSION
Transiently replicating SGRs have been instrumental in the
elucidation of the functions of the HCV non-structural pro-
teins, mechanisms of genome replication and development
of DAAs. The three SGRs which have so far been reported
for GT3, derived from two different isolates, are limited in
their ability to replicate efficiently in a transient system and
only replicate efficiently following selection with neomycin
[16]. However, such stable replicon-harbouring cell systems
are of limited use for development of DAAs and do not
allow investigation into the mechanisms of resistance, since
the most widely reported RAS within NS5A – Y93H – is
associated with a fitness cost [27]. As they contain pre-exist-
ing active genome replication complexes they are not able to
model early stages in the infectious cycle – namely transla-
tion of incoming genomic RNA, and subsequent establish-
ment of replication complexes by the newly synthesized
non-structural proteins. As such, they are a less representa-
tive model of HCV replication than transient SGRs. Tran-
sient replication of S310 was measured but showed
luciferase levels of only several orders of magnitude lower
than input translation at 4 hpe, and replication of the S52
SGR developed in transfected-and-cured Lunet cells did not
replicate efficiently until 7 days post-transfection [17, 18].
The S52 SGR reported by Saeed et al. did not replicate tran-
siently in our hands in Huh7.5 cells, which have a defect in
innate intracellular immunity due to a mutation in RIG-I
[28]. As reported [16], we were able to select stable SGR-
harbouring cells using G418 and we identified an additional
culture adaptation, A1672V in NS4A. When introduced
into the S52 CpG/UpA-low luciferase SGR by site-directed
mutagenesis, this conferred high levels of replication but
only in cells expressing both PIV5 V and SEC14L2 (Fig. 4).
The A1672V substitution is located in the hydrophobic N-
terminal, membrane-anchoring domain. It is not clear why
a substitution from a hydrophobic to polar amino acid side
chain in this region proves to be so beneficial to replication.
However, it is interesting to note that in a recombinant
genome comprising the S52 5¢UTR-NS5A with JFH-1-
derived NS5B and 3¢UTR (5-5A recombinant), A1672S is
one of the three key mutations required for efficient replica-
tion, the others being F1464L in NS3 and D2979G in NS5B
(the LSG combination) [29]. In contrast, the group of Jens
Bukh also recently generated a full-length GT3a genome
(DBN3acc) which replicated as efficiently as JFH-1 [30], but
this did not contain substitutions at any of the sites identi-
fied in our study; however, one of the 17 substitutions in
purposes all data were combined on to a single graph. Cells were harvested for luciferase assay at the indicated time points. Relative
luciferase units are expressed as the ratio to 4 hpe. Error bars represent the standard error of the mean of four experimental repeats.
**P0.01, ***P0.001, ****P0.0001.
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this construct was Y1680C in NS4A. Clearly therefore, in
GT3, NS4A is a hot-spot for culture-adaptive mutations
pointing to a key role for this small protein in virus–
host interactions.
We investigated a number of approaches to increase the
replication fitness of the SGR or to modulate the host cell
environment to increase permissibility to SGR replication.
DNA from different types of organism differs in CpG and
UpA dinucleotide frequency; in particular, as luciferase is
insect-derived, it contains a higher frequency than
mammalian genes. Optimization of CpG and UpA dinucle-
otide frequency increases the replication capacity of a num-
ber of viruses [31]. This effect is thought to be mediated by
avoiding an as yet uncharacterized innate immune recogni-
tion of high-CpG/UpA sequences [32]. In our hands
replacement of the Feo reporter cassette with a CpG/UpA-
low luciferase did not by itself allow detectable replication of
S52, despite conferring a fourfold increase in replication on
Con1 SGR, although we note that others did observe an
enhancement of S52 replication [23].
Fig. 4. Replication of culture-adapted S52 SGR. (a) Two micrograms of the indicated RNA transcripts were electroporated into VSEC
cells. (b) Two micrograms of S52(A1672V) RNA were electroporated into the indicated cell lines. Cells were harvested for luciferase
assay at the indicated time points. Luciferase activity is presented as absolute values.
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The parainfluenza virus type 5 (PIV5) V protein blocks
STAT1-mediated immune activation by binding directly to
STAT1 and inhibiting downstream interferon-a activation
[25, 33, 34]. It has been shown that stable expression of the
V protein enhances replication of HCV in human foetal
liver cells [35]. Recently, the host cell protein SEC14L2 was
found to allow replication of an unadapted SGR or isolates
from patient samples including GT3. This is thought to
work by accumulation of vitamin E, which provides protec-
tion against lipid peroxidation [26]. By combining both V
and SEC14L2, together with a CpG/UpA-low luciferase and
the A1672V culture adaptation in NS4A, we were able to
establish a transiently replicating S52 SGR.
The utility of this transiently replicating GT3 SGR in antivi-
ral development was tested by treatment with NS5A inhibi-
tors DCV and LDV, NS5B inhibitor SOF and ribavirin,
which is recommended alongside DAA combination thera-
pies, particularly with respect to GT3 treatment. The NHS
Extended Access Program found that the SVR achieved with
a SOF/LDV combination compared to SOF/DCV was
markedly less for GT3 patients [11]. SOF is reported to be
pan-genotypic, and our data agree with this as we observed
no differences in the EC50 for SOF between GT1, GT2 and
GT3 SGRs (Fig. 5c). In contrast, and in agreement with clini-
cal trial reports, we observed that the GT3 EC50 for DCV and
LDV was significantly higher than for GT1, and the GT3
Fig. 5. Effect of clinically approved anti-HCV compounds on S52 SGR replication. 8103 VSEC cells electroporated with either S52
(A1672V), S52(A1672V)(Y93H), Con1 CpG/UpA-low SGR or SGR-Feo-JFH-1 were seeded into each well of a white 96-well plate. Cells
were treated after either 4 h (Con1/JFH-1) or 24 h (S52), with the indicated concentrations of DCV (a), LDV (b), SOF (c) or ribavirin (d)
for 72 h before being harvested for luciferase assay. DMSO vehicle concentration was 0.25%. Relative luciferase units are expressed
as a percentage of vehicle-only treated cells and 50% effective concentrations calculated using Graphpad software.
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EC50 for LDV was several orders of magnitude higher than
DCV. This also concurs with data published recently on the
full-length GT3a genome (DBN3acc), for which LDV was
found to be significantly less effective [30]. DBN3acc was also
more resistant to both DCV and LDV, compared to a GT1
virus. The results obtained here using a transient SGR system
thus compare favourably to those obtained using full-length
infectious virus assays. In addition, Y93H RAS in NS5A was
significantly less sensitive to both NS5A inhibitors than
wild-type S52. We demonstrated that Y93H was selected
during passage of stable S52-harbouring cells in the presence
of DCV. To the best of our knowledge this is the first such
observation of selection for DCV resistance in a complete
GT3 SGR in vitro, although Y93H was also selected following
DCV treatment of a chimeric SGR containing a hybrid
NS5A protein (amino acids 1–429 of GT3) in a GT2a (JFH-
1) backbone [20]. In the latter study the authors also
observed a modest fitness cost of the Y93H RAS and identi-
fied a second RAS, L31F, that was not seen in our study. We
did not observe a Y93H-associated fitness cost in stable SGR-
harbouring cells, but in the transient assay described here
Y93H exhibited a lower replication capacity. Taken together,
these observations suggest that development of resistance,
and the corresponding fitness cost, depend on the sequence
context, underscoring the importance of working with intact
(i.e. non-chimeric) SGRs or infectious viruses.
This work details the development of an efficiently replicat-
ing GT3 SGR which can be applied to the discovery and
Table 2. EC50 values for transient SGR
DCV LDV SOF Ribavirin
Con1 EC50 0.98 pM 0.32 pM 27.9 nM 8.7 µM
JFH-1 EC50 3.9 pM 0.98 nM 51.2 nM 22.9 µM
Fold over Con1 3.97 3038 1.83 6.27
S52 EC50 63 pM 200 nM 6.3 nM 12.6 µM
Fold over Con1 64.2 614 000 0.23 4.27
S52 Y93H EC50 4.5 µM >40 µM 22.7 nM 23.9 µM
Fold over Con1 4 600 000 ND 0.81 7.25
Fold over S52 71 600 ND 3.6 1.7
ND, Not determined.
Fig. 6. Comparison of transient and stable replication of S52 SGR. (a) Cells harbouring SGR-Feo-S52, or SGR-Feo-S52 selected with
DCV, were seeded at a density of 8103 per well of a 96-well plate and harvested for luciferase assay after 72 h. Luciferase activity is
presented as absolute values. (b) Two micrograms of RNA transcribed from SGR-neo-S52 or SGR-neo-S52(Y93H) were electroporated
into Huh7.5 cells and seeded at a density of 2105 cells per well of a 6-well plate. Cells were selected with 0.5mg ml 1 G418 from 48
hpe for three weeks before being fixed and stained with 0.5% crystal violet in 10% formalin and manually counted. (c)
Two micrograms of RNA transcribed from S52(A1672V) or S52(A1672V) Y93H was electroporated into VSEC cells and 1104 cells
were harvested for luciferase assay at 96 hpe. ***P0.001, ****P0.0001, ns: not significant.
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development of combination therapies, analysis of resistance
and further study into the differences between this and other
genotypes, whichmay inform other aspects of HCV research.
METHODS
Plasmids
S52 feo (AII variant) SGR was obtained from Charles Rice
[16]. Con1 SGRs with wild-type or CpG/UpA-low luciferase
were obtained from Peter Simmonds [23]. Insertion of
CpG/UpA-low luciferase into S52 feo required the insertion
of a unique AscI site, which resulted in mutation of the last
residue of the 19-residue section of core protein, immedi-
ately upstream of the luciferase start codon, from proline to
alanine; translation of the reporter was not compromised.
Primer sequences available on request. Plasmid containing
SEC14L2 for lentiviral transduction was obtained from
Peter Simmonds. Site-directed mutagenesis was performed
using the QuikChange protocol from Stratagene and sub-
cloning was carried out according to standard techniques.
Modified SGRs were verified by sequence analysis.
Cell lines and reagents
Huh7.5 cells were maintained in DMEM containing
4.5 g l 1 glucose, 2mM glutathione and sodium pyruvate
(Lonza) supplemented with 10% FBS (Sera Laboratories
International), penicillin/streptomycin (Sigma) and non-
essential amino acids (Lonza) in a humidified 37

C, 5%
CO2 incubator. Huh7.5 cells stably transfected with parain-
fluenza virus 5 (PIV-5) V protein (Huh7.5-V) were obtained
from Stephen Griffin (University of Leeds). Huh7.5-V cells
were maintained in DMEM as described above with
0.5mg ml 1 G418. Lentiviruses were generated using a plas-
mid containing SEC14L2 as reported [23], and transduced
Huh7.5 and Huh7.5-V cell lines were were selected with
2 µgml 1 puromycin (Huh7.5) or both G418 and puromy-
cin (Huh7.5-V).
RNA synthesis and SGR replication assay in
cultured cells
SGR plasmids were linearized with XbaI (New England
Biolabs) and RNA was transcribed using a T7 transcription
kit (Promega) according to the manufacturer’s instructions.
Two micrograms of RNA transcripts were electroporated
into 2106 cells in diethyl pyrocarbonate (DEPC)-phos-
phate-buffered saline (PBS) using a square-wave protocol at
260 V for 25ms. For selection of stable, SGR-harbouring
cells, 106 electroporated cells were seeded into 10 cm2 dishes
and selected with 0.5mg ml 1 G418 from 48 hpe. Surviving
cells were pooled into polyclonal populations for further
analysis. For replication assays, electroporated cells were
seeded in white 96-well plates at a density of 104 cells per
well in four assay replicates for each. Following incubation,
cells were washed with 1PBS and lysed in 30 µl passive
lysis buffer (PLB: Promega). Luciferase activity was mea-
sured on a FLUOROstar Optima plate reader (BMG Lab-
tech) primed with Luciferase Assay Reagent I (LAR I,
Promega).
Immunoblotting
Cells were washed twice in PBS and lysed in Glasgow Lysis
Buffer [GLB; 1% (vol/vol) Triton X-100, 120mM KCl,
30mM NaCl, 5mM MgCl2, 10% (vol/vol) glycerol, 10mM
PIPES [piperazine-N,N¢-bis(2-ethanesulfonic acid)]-NaOH,
pH 7.2, with protease and phosphatase inhibitors], and clar-
ified by centrifugation at 2800 g for 5min at 4

C. Protein
concentration was measured for normalization by bicincho-
ninic acid assay (BCA, Pierce). Proteins were resolved on
7.5% polyacrylamide gel before being transferred to polyvi-
nylidene difluoride (PVDF) membrane. Membranes were
blocked in 50% (v/v) Odyssey blocking buffer (LI-COR) in
Tris-buffered saline (TBS) and incubated in primary anti-
bodies overnight at 4 ˚C and infra-red tagged secondary
antibodies (LI-COR) at room temperature for 1 h. Primary
antibodies used were anti-NS5A (sheep, 1 : 5000, [36]), anti-
V5 tag (rabbit, 1 : 1000, Cell Signalling Technologies) and
anti b-actin (mouse, 1 : 20 000, abcam). Secondary antibod-
ies were anti-sheep, anti-rabbit (both 800 nm) and anti-
mouse (680 nm), all used at 1 : 15 000. Membranes were
imaged using a LI-COR Odyssey infra-red imaging system.
Immunofluorescence
Cells were washed once in PBS, fixed for 10min in 4% (w/v)
paraformaldehyde (PFA) and permeabilized in 0.1% (v/v)
Triton X-100 in PBS. Fixed cells were immunostained with
anti-NS5A (as described above) at 1 : 2000 and anti-sheep
(488 nm, AlexaFluor). Cells were mounted using Prolong
Gold antifade mountant with DAPI and imaged using a Carl
Zeiss LSM 700 inverted microscope and Zeiss Zen 2012
software.
RNA extraction from cells and PCR
Stable SGR-harbouring cells were harvested in TRIZol
(Invitrogen Life Technologies) and RNA purified according
to the manufacturers’ instructions. One microgram of RNA
was reverse-transcribed using Superscript II (Invitrogen)
and random hexamer primers. Two microlitres of this
cDNA were used as a template for PCR amplification of
SEC14L2 or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as a loading control. DNA fragments were
resolved on 1% agarose gel.
Next-generation sequencing (NGS)
Viral RNA was extracted from cells stably harbouring the
S52 SGR using the RNeasy plus mini kit (Qiagen). PCR
amplification and NGS was performed as previously
described [37] with modifications. Briefly, the SGR was
amplified using HCV GT3a genotype-specific primers for
four overlapping amplicons spanning the HCV GT3a non-
structural genes. The forward primers for the NS3_4A frag-
ment were redesigned to be complementary to the EMCV
IRES region of the SGR (primer sequences available upon
request). Viral RNA was amplified by single-step RT-PCR
(Superscript III Reverse Transcriptase, Invitrogen), followed
by nested or semi-nested PCR. PCR products were purified
using the QIAQuick kit (QIAGEN) and quantified by Qubit
dsDNA Broad Range and High Sensitivity Assay Kits and
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the Qubit 2.0 Fluorometer (Life Technologies). Alternate
amplicons were pooled in two reactions of equimolar
amounts and 1 ng µl 1 of the pooled DNA was used for
library preparation (Nextera XT DNA sample preparation
kit; Illumina) according to manufacturer’s instructions.
Indexed libraries were sequenced using Illumina MiSeq
deep sequencing reagent kit v2 (Illumina).
Treatment with antiviral compounds
VSEC cells (described above) were electroporated with 2 µg
SGR RNA transcripts, and 104 electroporated cells were
seeded into white 96-well plates. Cells electroporated with
Con1 and JFH-1 were treated with the indicated concentra-
tions of DCV, LDV (both SelleckChem), SOF (Gilead) or
ribavirin (Sigma) in duplicate with 0.25% (v/v) final DMSO
at 4 hpe for 72 h. Cells electroporated with S52 wild-type
and Y93H were treated at 24 hpe for 72 h, following
a preliminary observation that replication is not reliably
detected until 96 hpe. This allowed a constant treatment
duration of 72 h for all electroporated cells. Cells were har-
vested for luciferase after 72 h treatment as described above.
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